The Anabolic Effects of Vitamin D-Binding Protein-Macrophage Activating Factor (DBP-MAF) and a Novel Small Peptide on Bone

Critical Reviews in Eukaryotic Gene Expression

Volumn 13, Issue 2-4 SPEC. ISS., 2003, Pages 277-284

  Schneider, Gary B ^a   Grecco, Kristina J ^a   Safadi, Fayez F ^b   Popoff, Steven N ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone formation; Osteogenesis; Osteoinduction; Osteopenia; Osteoporosis

Indexed keywords

MACROPHAGE ACTIVATING FACTOR; PEPTIDE; SODIUM CHLORIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; VITAMIN D BINDING PROTEIN MACROPHAGE ACTIVATING FACTOR;

ALBERS SCHOENBERG DISEASE; ALLELE; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE DEFECT; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE MARROW; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DENSITOMETRY; FRACTURE; GENE MUTATION; GLYCOSYLATION; HISTOLOGY; JOINT PROSTHESIS; LONG BONE; METAPHYSIS; NEWBORN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; SKELETON MALFORMATION; SPINE SURGERY;

ANABOLIC AGENTS; ANIMALS; ANIMALS, NEWBORN; BONE AND BONES; DENSITOMETRY; FEMALE; FEMUR; GLYCOPEPTIDES; HUMANS; MACROPHAGE-ACTIVATING FACTORS; MALE; OSTEOPOROSIS; PEPTIDES; RATS; TIBIA; TIME FACTORS; VITAMIN D-BINDING PROTEIN;

ANIMALIA;

EID: 0347624658     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.180     Document Type: Article

References (21)

1. Boden S, Kang J, Sandhog H, Heller J (2002): Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans. Spine 27:2662-2673.
2. Dempster D, Cosman F, Kurland E, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001): Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
3. Haddad J, Walgate J (1976):25-Hydroxyvitamin D transport in human plasma: Isolation and partial characterization of calcifidiol-binding protein. J Biol Chem 251:4426-4432.
4. Haddad J (1982): Human serum binding protein for vitamin D and its metabolites: Evidence that actin is the DBP binding component in human skeletal muscle. Arch Biochem Biophys 213:538-544.
5. Hock J, Gera I (1992): Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72.
6. Kurland E, Cosman F, McMahon D, Rosen C, Lindsay R, Bilezikian J (2000): Therapy of idiopathic osteoporosis in men with parathyroid hormone: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076.
7. Li M, Ma Y, Jee W, Underwood R, Sietsema W (1995): An in vivo model for the rapid assessment of skeletal effects of anabolic agents. Bone 17:243S-247S.
8. Neer R, Amaud C, Zanchetta R, Prince R, Gaich G, Reginster J-Y, Hodsman A, Eriksen E, Shalom S, Genant H, Wang Q, Mitlak B (2001): Effect of parathyroid hormone (I-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 344:1434-1441.
9. Popoff S, Schneider G (1994): Conversion of the vitamin D-binding protein to a macrophage activating factor: Associated defects in osteopetrotic mutations. In Norman AW (ed): Vitamin D, a pluripotent steroid hormone: Structural studies, molecular endocrinology and clinical applications. Berlin, New York: Walter deGruyter, 693-701.
10. Popoff S, Schneider G (1996): Animal models of osteopetrosis: The impact of recent molecular developments on novel strategies for therapeutic intervention. Mol Med Today 2:349-358.
11. Safadi F, Xu J, Smock S, Kanaan R, Selim A, Odgren P, Marks S, Jr, Owen T, Popff S (2003): Expression of connective tissue growth factor in bone: Its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. J Cell Physiol 196:51-62.
12. Schneider G, Benis K, Flay N, Ireland R, Popoff S (1995): Effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations. Bone 16:657-662.
13. Schneider G, Key L Jr, Popoff S (1998): Osteopetrosis: Therapeutic strategies. The Endocrinologist 8:409-417.
14. 3 does not influence this activity. J Cell Biochem 81:535-546.
15. Tam C, Heersche J, Murray T, Parsons J (1982): Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 110:506-512.
16. Van Baelen H, Bouillon R, DeMoor P (1980): Vitamin D-binding protein (Gc-globulin) binds actin. J Biol Chem 255:2270-2272.
17. Viau M, Constans H, Debray H, Montreuil J (1983): Isolation and characterization of the o-glycan chain of the human vitamin D-binding protein. Biochem Biophys Res Comm 117:324-331.
18. Walker D, Wright N (2002): Bone morphogenetic proteins and spinal fusion. Neurosurg Focus 13:6.
19. Yamamoto N, Homma S (1991): Vitamin D3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci U S A 88:8539-8545.
20. 3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of β-galactosidase of B cells and sialidase of T cells. J Immunol 151:2794-2802.
21. Yamamoto N, Lindsay D, Naraparaju V, Ireland R, Popoff S (1994): A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol 152:5100-5107.